La Jolla Pharmaceutical Long Term Debt

La Jolla Pharmaceutical's long-term debt stands at $75K as of June 2022. That compares with $2.6M in the prior-year period — down 97.1% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

La Jolla Pharmaceutical reported $75K in long-term debt versus $2.6M a year earlier — a 97.1% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $2.6M in the prior-year period — down 97.1% year over year. Sustained growth in long-term debt can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how La Jolla Pharmaceutical's long-term debt evolved across reporting periods, while the comparison chart places LJPC next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, long-term debt is commonly used to spot outliers. La Jolla Pharmaceutical's reading of $75K is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.